Efficacy of Daratumumab‐Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report

Abstract

ABSTRACT Introduction Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab‐based regimens have been reported yet. Case Presentation Here, a 64‐year‐old man with pulmonary plasmacytoma received daratumumab‐based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug‐induced neuropathy and JAK2‐mutated myeloproliferative neoplasm with marked splenomegaly. Conclusions We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.

Keywords

• daratumumab
• extramedullary disease
• multiple myeloma